IHT Wealth Management LLC Purchases 436 Shares of Becton, Dickinson and Company (NYSE:BDX)

IHT Wealth Management LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 16.7% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 3,047 shares of the medical instruments supplier’s stock after acquiring an additional 436 shares during the period. IHT Wealth Management LLC’s holdings in Becton, Dickinson and Company were worth $735,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its position in Becton, Dickinson and Company by 79.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock worth $720,089,000 after acquiring an additional 1,317,723 shares during the last quarter. M&G Plc grew its position in Becton, Dickinson and Company by 0.9% during the 2nd quarter. M&G Plc now owns 709,259 shares of the medical instruments supplier’s stock worth $165,967,000 after acquiring an additional 6,052 shares during the last quarter. Benson Investment Management Company Inc. grew its position in Becton, Dickinson and Company by 13.2% during the 3rd quarter. Benson Investment Management Company Inc. now owns 22,315 shares of the medical instruments supplier’s stock worth $5,380,000 after acquiring an additional 2,602 shares during the last quarter. Swedbank AB grew its position in Becton, Dickinson and Company by 1.8% during the 3rd quarter. Swedbank AB now owns 150,838 shares of the medical instruments supplier’s stock worth $36,367,000 after acquiring an additional 2,729 shares during the last quarter. Finally, Curi RMB Capital LLC lifted its holdings in Becton, Dickinson and Company by 18.1% during the 3rd quarter. Curi RMB Capital LLC now owns 84,873 shares of the medical instruments supplier’s stock worth $20,463,000 after buying an additional 13,030 shares during the period. Institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on BDX. Evercore ISI lifted their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $255.00 to $275.00 in a report on Tuesday, October 1st. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Becton, Dickinson and Company has an average rating of “Buy” and an average target price of $283.50.

Becton, Dickinson and Company Stock Down 1.0 %

Shares of NYSE:BDX opened at $220.02 on Friday. The company has a market capitalization of $63.61 billion, a price-to-earnings ratio of 37.04, a P/E/G ratio of 1.65 and a beta of 0.41. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.17 and a quick ratio of 0.74. The business’s 50-day moving average is $232.60 and its 200-day moving average is $233.60. Becton, Dickinson and Company has a 1 year low of $218.75 and a 1 year high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.77 by $0.04. The company had revenue of $5.44 billion for the quarter, compared to the consensus estimate of $5.38 billion. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm’s revenue was up 6.9% compared to the same quarter last year. During the same period in the previous year, the business earned $3.42 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 31st. Stockholders of record on Monday, December 9th will be paid a $1.04 dividend. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.89%. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. The ex-dividend date is Monday, December 9th. Becton, Dickinson and Company’s payout ratio is currently 70.03%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.